



# Notice of AGM

September 28, 2017 9:15 PM EDT

Released : September 28, 2017 17:15

RNS Number : 1589S

MaxCyte, Inc.

28 September 2017

## **MaxCyte, Inc.**

("MaxCyte" or the "Company")

### **Notification of Annual General Meeting**

**Maryland, USA - 28 September 2017:** MaxCyte (LSE: MXCT, MXCR), a US-based global company driving the acceleration of the discovery, development, manufacturing and commercialisation of next-generation, cell-based medicines, announces that formal notice and resolutions of the Company's AGM, along with a letter from the Chairman and the Annual Meeting Proxy Card and Form of Direction, has been circulated to Shareholders.

These documents are also available in electronic form on the Company's website: [www.maxcyte.com](http://www.maxcyte.com).

The Annual General Meeting of Stockholders is planned to be held at 11 a.m. GMT on 31 October 2017 at InterContinental London Park Lane, One Hamilton Place, Park Lane, London W1J 7QY, United Kingdom.

**For further information, please contact:**

#### **MaxCyte Inc.**

Doug Doerfler, Chief Executive Officer

Ron Holtz, Chief Financial Officer

+1 301 944 1660

***Nominated Adviser and Broker***

**Panmure Gordon**

Freddy Crossley (Corporate Finance)

+44 (0) 20 7886 2500

Duncan Monteith

Ryan McCarthy

Tom Salvesen (Corporate Broking)

***Financial PR Adviser***

**Consilium Strategic Communications**

Mary-Jane Elliott

+44 (0)203 709 5700

Chris Welsh

[maxcyte@consilium-comms.com](mailto:maxcyte@consilium-comms.com)

Lindsey Neville

**About MaxCyte**

MaxCyte (LSE: MXCT, MXCR) is a US-based global company driving the acceleration of the discovery, development, manufacturing and commercialization of next-generation, cell-based medicines. The Company provides its patented, high-performance cell engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing, and cell therapy, including gene editing and immuno-oncology. With its robust delivery platform, MaxCyte's team of scientific experts helps its partners to unlock their product potential and solve problems. This platform allows for the engineering of nearly all cell types, including human primary cells, with any molecule, at any scale. It also provides a high degree of consistency and minimal cell disturbance, thereby facilitating rapid, large-scale, clinical and commercial grade cell engineering in a non-viral system and with low-toxicity concerns. The Company's cell-engineering platform is FDA-accredited, providing MaxCyte's customers and partners with an established regulatory path to commercialize cell-based medicines. MaxCyte is also developing CARMA, its proprietary, breakthrough platform in immuno-oncology, to rapidly manufacture CAR therapies for a broad range of cancer indications, including solid tumours where existing CAR-T approaches face significant challenges. For more information, visit <http://www.maxcyte.com/>.

This information is provided by RNS  
The company news service from the London Stock Exchange

END

NOABLGDCXBDBGRI